Scholarlink

Background <p>Prostate cancer (PCa) is the second leading cause of death in men and is highly prone to metastasis. This study aims to develop the novel immuno-PET/CT tracer targeting trophoblast cell surface antigen 2 (Trop2), a transmembrane protein overexpressed in aggressive prostate malignancies, and to investigate its diagnostic value in preclinical studies as well as its potential utility in detecting metastases in PCa patients.</p> Methods <p>Integrated analysis of TCGA, GEO, and HPA datasets revealed Trop2 overexpression in prostate adenocarcinoma. By labeling two Trop2-targeted nanobodies (His-tagged T4 and His-tag-free RT4) with <sup>68</sup>Ga and <sup>18</sup>F, we synthesized three radiotracers, [<sup>68</sup>Ga]Ga-NOTA-T4, [<sup>18</sup>F]AlF-RESCA-T4, and [<sup>18</sup>F]AlF-RESCA-RT4. Preclinical validation included cellular assays and xenograft studies for <sup>68</sup>Ga/<sup>18</sup>F-T4 variants, followed by a first-in-human trial evaluating [<sup>18</sup>F]AlF-RESCA-RT4 in ten treatment-naïve PCa patients.</p> Results <p>Bioinformatics analysis demonstrated Trop2 as a promising target for PCa diagnosis and treatment. In preclinical studies, both [<sup>68</sup>Ga]Ga-NOTA-T4 and [<sup>18</sup>F]AlF-RESCA-T4 illustrated high affinity to Trop2, specific tumor uptake (4.33 ± 0.38&#xa0;%ID/g and 5.50 ± 0.69&#xa0;%ID/g at 60&#xa0;min, respectively) in Trop2-positive xenograft mouse models with minimal background distribution. In the translational study, [<sup>18</sup>F]AlF-RESCA-RT4 outperformed standard [<sup>18</sup>F]-FDG imaging in metastatic prostate cancer patients, detecting 62.4% more lymph node metastases (SUVmax 21.58 ± 13.12 vs. 4.80 ± 1.77) and 69.4% more bone lesions (SUVmax 7.83 ± 4.32 vs. 4.72 ± 1.22). No adverse events were observed.</p> Conclusions <p>This work successfully establishes that Trop2 is a new biomarker for PCa, and Trop2 immuno-PET/CT imaging can detect PCa lymph node and osseous metastases. The superior tumor-to-background contrast and clinical safety of [<sup>18</sup>F]AlF-RESCA-RT4 support its translational potential to guide Trop2-targeted therapies and enhance personalized treatment strategies.</p> Trial registration <p>NCT06851663. Retrospectively registered 02/24/2025.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Trop2 immuno-PET/CT imaging of prostate cancer: a proof-of-concept translational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月31日

查看全文
  • Xingru Long,
  • Shuxian An,
  • Xuanbingning Nian,
  • Dongsheng Xu,
  • Weijun Wei,
  • Xiaoli Lan,
  • Liang Dong,
  • Dawei Jiang

摘要

Background

Prostate cancer (PCa) is the second leading cause of death in men and is highly prone to metastasis. This study aims to develop the novel immuno-PET/CT tracer targeting trophoblast cell surface antigen 2 (Trop2), a transmembrane protein overexpressed in aggressive prostate malignancies, and to investigate its diagnostic value in preclinical studies as well as its potential utility in detecting metastases in PCa patients.

Methods

Integrated analysis of TCGA, GEO, and HPA datasets revealed Trop2 overexpression in prostate adenocarcinoma. By labeling two Trop2-targeted nanobodies (His-tagged T4 and His-tag-free RT4) with 68Ga and 18F, we synthesized three radiotracers, [68Ga]Ga-NOTA-T4, [18F]AlF-RESCA-T4, and [18F]AlF-RESCA-RT4. Preclinical validation included cellular assays and xenograft studies for 68Ga/18F-T4 variants, followed by a first-in-human trial evaluating [18F]AlF-RESCA-RT4 in ten treatment-naïve PCa patients.

Results

Bioinformatics analysis demonstrated Trop2 as a promising target for PCa diagnosis and treatment. In preclinical studies, both [68Ga]Ga-NOTA-T4 and [18F]AlF-RESCA-T4 illustrated high affinity to Trop2, specific tumor uptake (4.33 ± 0.38 %ID/g and 5.50 ± 0.69 %ID/g at 60 min, respectively) in Trop2-positive xenograft mouse models with minimal background distribution. In the translational study, [18F]AlF-RESCA-RT4 outperformed standard [18F]-FDG imaging in metastatic prostate cancer patients, detecting 62.4% more lymph node metastases (SUVmax 21.58 ± 13.12 vs. 4.80 ± 1.77) and 69.4% more bone lesions (SUVmax 7.83 ± 4.32 vs. 4.72 ± 1.22). No adverse events were observed.

Conclusions

This work successfully establishes that Trop2 is a new biomarker for PCa, and Trop2 immuno-PET/CT imaging can detect PCa lymph node and osseous metastases. The superior tumor-to-background contrast and clinical safety of [18F]AlF-RESCA-RT4 support its translational potential to guide Trop2-targeted therapies and enhance personalized treatment strategies.

Trial registration

NCT06851663. Retrospectively registered 02/24/2025.